Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Cabozantinib
Trade Name Cometriq
Synonyms Cabometyx|Cabozantinib-s-malate|XL184
Drug Descriptions

Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov).
DrugClasses AXL Inhibitor 29 FLT3 Inhibitor 62 KIT Inhibitor 56 MET Inhibitor 57 RET Inhibitor 50 ROS1 Inhibitor 20 VEGFR2 Inhibitor 36
CAS Registry Number 1140909-48-3
NCIT ID C97938

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
177Lu-girentuximab + Cabozantinib + Nivolumab 177Lu-girentuximab Cabozantinib Nivolumab 0 1
Abiraterone + Cabozantinib Abiraterone Cabozantinib 0 0
Abiraterone + Cabozantinib + Nivolumab + Prednisone Abiraterone Cabozantinib Nivolumab Prednisone 0 1
Afatinib + Cabozantinib Afatinib Cabozantinib 0 0
Atezolizumab + Cabozantinib Atezolizumab Cabozantinib 0 15
Atezolizumab + Cabozantinib + Nab-paclitaxel Atezolizumab Cabozantinib Nab-paclitaxel 0 0
Atezolizumab + Cabozantinib + Yttrium-90 microsphere therapy Atezolizumab Cabozantinib Yttrium-90 microsphere therapy 0 1
Autologous alpha-DC1/TBVA vaccine + Cabozantinib Autologous alpha-DC1/TBVA vaccine Cabozantinib 0 1
AVB-S6-500 + Cabozantinib AVB-S6-500 Cabozantinib 0 1
Avelumab + Cabozantinib Avelumab Cabozantinib 0 3
Belzutifan + Cabozantinib Belzutifan Cabozantinib 0 1
Cabozantinib Cabozantinib 24 88
Cabozantinib + Carfilzomib + Dexamethasone Cabozantinib Carfilzomib Dexamethasone 0 1
Cabozantinib + CBM588 + Nivolumab CBM588 Cabozantinib Nivolumab 0 1
Cabozantinib + Cetuximab Cabozantinib Cetuximab 0 1
Cabozantinib + Chloroquine Cabozantinib Chloroquine 0 0
Cabozantinib + Cisplatin + Doxorubicin + Methotrexate Cabozantinib Cisplatin Doxorubicin Methotrexate 0 1
Cabozantinib + Conteltinib Cabozantinib Conteltinib 0 0
Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan Cabozantinib Cyclophosphamide Filgrastim Topotecan 0 1
Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib Cyclophosphamide Pegfilgrastim Topotecan 0 1
Cabozantinib + Docetaxel Cabozantinib Docetaxel 0 1
Cabozantinib + Dostarlimab-gxly Cabozantinib Dostarlimab-gxly 0 1
Cabozantinib + Doxorubicin + Methotrexate Cabozantinib Doxorubicin Methotrexate 0 1
Cabozantinib + Durvalumab Cabozantinib Durvalumab 0 2
Cabozantinib + Enfortumab vedotin-ejfv Cabozantinib Enfortumab vedotin-ejfv 0 1
Cabozantinib + Erlotinib Cabozantinib Erlotinib 0 2
Cabozantinib + Exemestane + Trastuzumab Cabozantinib Exemestane Trastuzumab 0 0
Cabozantinib + Fulvestrant Cabozantinib Fulvestrant 0 1
Cabozantinib + Gefitinib Cabozantinib Gefitinib 0 0
Cabozantinib + Gefitinib + Pembrolizumab Cabozantinib Gefitinib Pembrolizumab 0 0
Cabozantinib + Gemcitabine Cabozantinib Gemcitabine 0 1
Cabozantinib + Infigratinib Cabozantinib Infigratinib 0 0
Cabozantinib + Ipilimumab + Nivolumab Cabozantinib Ipilimumab Nivolumab 0 14
Cabozantinib + Isotretinoin Cabozantinib Isotretinoin 0 1
Cabozantinib + Lanreotide acetate Cabozantinib Lanreotide acetate 0 1
Cabozantinib + lutetium Lu 177 dotatate Cabozantinib lutetium Lu 177 dotatate 0 1
Cabozantinib + lutetium Lu 177 vipivotide tetraxetan Cabozantinib lutetium Lu 177 vipivotide tetraxetan 0 1
Cabozantinib + Navitoclax Cabozantinib Navitoclax 0 0
Cabozantinib + Niraparib Cabozantinib Niraparib 0 1
Cabozantinib + Nivolumab Cabozantinib Nivolumab 0 25
Cabozantinib + Osimertinib Cabozantinib Osimertinib 0 0
Cabozantinib + Pamiparib Cabozantinib Pamiparib 0 1
Cabozantinib + Panitumumab Cabozantinib Panitumumab 0 1
Cabozantinib + Pembrolizumab Cabozantinib Pembrolizumab 0 10
Cabozantinib + Pemetrexed Disodium Cabozantinib Pemetrexed Disodium 0 1
Cabozantinib + Radium Ra 223 dichloride Cabozantinib Radium Ra 223 dichloride 0 1
Cabozantinib + SBI-0206965 Cabozantinib SBI-0206965 0 0
Cabozantinib + Sunitinib Cabozantinib Sunitinib 0 2
Cabozantinib + Telaglenastat Cabozantinib Telaglenastat 0 2
Cabozantinib + Temozolomide Cabozantinib Temozolomide 0 2
Cabozantinib + Trametinib Cabozantinib Trametinib 0 0
Cabozantinib + Trifluridine-tipiracil hydrochloride Cabozantinib Trifluridine-tipiracil hydrochloride 0 1
Cabozantinib + unspecified CTLA4 antibody + unspecified PD-1 antibody Cabozantinib unspecified CTLA4 antibody unspecified PD-1 antibody 0 0
Cabozantinib + Vandetanib Cabozantinib Vandetanib 0 1
Cabozantinib + Vemurafenib Cabozantinib Vemurafenib 0 1
Cabozantinib + XOMA 052 Cabozantinib XOMA 052 0 1


Additional content available in CKB BOOST